4.7 Article

Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 13, Pages 9330-9353

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00555

Keywords

-

Funding

  1. Ministry of Education, Youth and Sports at IMB PAS [RVO: 68378050-KAV-NPUI, LM2015063, LM2018130, NSC 2014/13/B/NZ1/03989]
  2. Ministry of Education, Youth and Sports at IMG [RVO: 68378050]
  3. Ministry of Education, Youth and Sports at UPOL [RVO: 61989592]
  4. College of Pharmacy at The Ohio State University
  5. NCI/NIH [P30CA016058]
  6. Drug Development Institute within The Ohio State University Comprehensive Cancer Center and Pelotonia

Ask authors/readers for more resources

The research synthesized a series of para-carborane estrogen receptor agonists with low nanomolar potency, over 200-fold selectivity for ER beta over ER alpha, limited off-target activity against other nuclear receptors, and minimal CYP450 inhibition at very high concentrations. These para-carborane ER beta selective agonists show favorable pharmacological properties compared to clinically developed ER beta agonists, supporting further evaluation of carborane-based selective estrogen receptor modulators.
Selective agonism of the estrogen receptor (ER) subtypes, ER alpha and ER beta, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffolds to model 17 beta-estradiol geometry in the design of ER beta selective agonists, with several proceeding to various stages of clinical development. Carborane scaffolds offer many unique advantages including the potential for novel ligand/receptor interactions but remain relatively unexplored. We synthesized a series of para-carborane estrogen receptor agonists revealing an ER beta selective structure-activity relationship. We report ER beta agonists with low nanomolar potency, greater than 200-fold selectivity for ER beta over ER alpha, limited off-target activity against other nuclear receptors, and only sparse CYP450 inhibition at very high micromolar concentrations. The pharmacological properties of our para-carborane ER beta selective agonists measure favorably against clinically developed ER beta agonists and support further evaluation of carborane-based selective estrogen receptor modulators.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available